Table 1.

Overview of trials included in external validation

Dose arm	Location	Ethnicities	Age	Comorbidities	Study arm size	Study length	Sputum sampling	Publication year	Reference
600 mg	South Africa	57% blacka	Median 34 y, range 18–61 ya	31% HIV‐positivea	15	7 d	Baseline and d 1, 2, 3, 4, 5, 6, and 7	2008	26
20 mg/kg	South Africa	No information available in publication	Mean 27 y, SD 9 y	23% HIV‐positive	13	5 d	Baseline and d 1, 2, 3, 4, and 5	2007	27
300 mg	South Africa	No information available in publication	No information available in publication	24% HIV‐positivea	16	5 d	Baseline and d 2 and 5	2005	28
600 mg	South Africa	No information available in publication	No information available in publication	24% HIV‐positivea	14	5 d	Baseline and d 2 and 5	2005	28

HIV, human immunodeficiency virus.

^aFor the whole trial and not the rifampicin arm specifically.